David R.GastfriendMDDFASAM

Psychiatry • Wareham, MA

Addiction

Chief Architect, ASAM's CONTINUUM(TM); Scientific Advisor, Treatment Research Institute

Join to view full profile

Dr. Gastfriend is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gastfriend's full profile

Already have an account?

Office
8 Beach Plum Ln
Wareham, MA 02571
Phone+1 617-283-6495
Is this information wrong?

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1981 - 1984
Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 1980 - 1981
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1980
Haverford CollegeBS, 1972 - 1976

Certifications & Licensure

NJ State Medical License 2020 - 2025
MA State Medical License 1982 - 2024
American Board of Psychiatry and Neurology Psychiatry

Awards, Honors, & Recognition

Distinguished Fellow American Society of Addiction Medicine, 2016
ASAE Gold Award American Society of Association Executives, 2016
John P. McGovern, M.D. Award and Lecture for highly meritorious contributions to addiction and society in public policy, treatment, research or prevention. American Society of Addiction Medicine, 2012
Fellow American College of Mental Health Administration, 2007
Champion in Healthcare Innovator Award Boston Business Journal, 2007
Innovators Combating Substance Abuse Nominee Robert Wood Johnson Foundation, 2002
Partners in Excellence Award Partners HealthCare, Inc., 1998, 2001
Mid-Career Investigator Award NIH - National Institute on Drug Abuse, 2000
ASAE Power of A Gold Award for CONTINUUM™ American Society of Association Executives, 2016
Named a Distinguished Fellow American Society of Addiction Medicine, 2016
John P. McGovern, M.D. Award and Lecture American Society of Addiction Medicine, 2012
ASAM Award for achievements during service to the Board of Directors American Society of Addiction Medicine, 2007
Champions in Healthcare Innovator Award Boston Business Journal, 2007
Outstanding Service Award American Society of Addiction Medicine, 2001
Nominee, Innovators Combating Substance Abuse Robert Wood Johnson Foundation, 2001
Mid-Career Investigator Award National Institute on Drug Abuse, 2000
Professional Specialty Program Award American Association for Medical Systems and Informatics, 1986
Fellowship in Community and Hospital Psychiatry American Psychiatric Association/Mead Johnson, 1982
National Institute of Mental Health Summer Fellowship Jefferson Medical College, 1977
Fels Research Institute Student Fellowship Temple University School of Medicine, 1975
Join now to see all

Clinical Trials

COMBINE (Acamprosate/Naltrexone) Start of enrollment: 1997 Aug 01
Completed
Phase 3
ALK21-010: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol-dependent Adults Start of enrollment: 2003 Oct 01
Completed
Phase 3
ALK21-006EXT: Long-term Safety of Medisorb® Naltrexone (VIVITROL®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]) Start of enrollment: 2004 Aug 01
Terminated
Phase 3
ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence Start of enrollment: 2008 Jun 01
Completed
Phase 3
ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals Start of enrollment: 2009 Mar 01
Completed
Phase 3
ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults Start of enrollment: 2002 Feb 01
Completed
Phase 3
ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®) Start of enrollment: 2002 Aug 01
Completed
Phase 3
ALK21-006: Long-Term Study of Medisorb® Naltrexone (VIVITROL®) Start of enrollment: 2003 Aug 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

3 citations
Thirty Years of TheASAMCriteria: A Report Card.
David R Gastfriend, David Mee-Lee> ;The Psychiatric Clinics of North America. 2022 Sep 1
4 citations
Practical Technology for Expanding and Improving Substance Use Disorder Treatment: Telehealth, Remote Monitoring, and Digital Health Interventions.
Mary M Sweeney, August F Holtyn, Maxine L Stitzer, David R Gastfriend> ;The Psychiatric Clinics of North America. 2022 Sep 1
14 citations
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
Paul H. Earley, Jacqueline Zummo, Asli Memisoglu, Bernard L. Silverman, David R. Gastfriend> ;Journal of Addiction Medicine. 2017 May 1
10 citations
A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri
Paul Crits-Christoph, Hannah M. Markell, Mary Beth Connolly Gibbons, Robert Gallop, Christie Lundy, Mark Stringer, David R. Gastfriend> ;Journal of Substance Abuse Treatment. 2016 Nov 1
14 citations
Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.
Paul Crits-Christoph, Christie Lundy, Mark Stringer, Robert Gallop, David R. Gastfriend> ;Journal of Substance Abuse Treatment. 2015 Sep 1
33 citations
Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
Edward V. Nunes, Evgeny Krupitsky, Walter Ling, Jacqueline Zummo, Asli Memisoglu, Bernard L. Silverman, David R. Gastfriend> ;Journal of Addiction Medicine. 2015 May 1
15 citations
Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.
Douglas L. Leslie, William Milchak, David R. Gastfriend, Philip L. Herschman, Edward O. Bixler, Diana L. Velott, Roger E. Meyer> ;The American Journal on Addictions. 2015 Apr 1
10 citations
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders
David R. Gastfriend> ;Annals of the New York Academy of Sciences. 2014 Oct 1
45 citations
Extended-release Naltrexone for Alcohol and Opioid Dependence : A Meta-Analysis of Healthcare Utilization Studies
Daniel M. Hartung, Dennis McCarty, Rongwei Fu, Katharina Wiest, Mady Chalk, David R. Gastfriend> ;Journal of Substance Abuse Treatment. 2014 Aug 1
[Injectable extended-release naltrexone for opioid dependence: an open label study of long-term safety and efficacy].
Evgeny Krupitsky, Edward V. Nunes, Walter Ling, David R. Gastfriend, Asli Memisoglu, Elena Blokhina, Bernard L. Silverman> ;Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2014 Jan 1
79 citations
Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
Evgeny Krupitsky, Edward V. Nunes, Walter Ling, David R. Gastfriend, Asli Memisoglu, Bernard L. Silverman> ;Addiction. 2013 Sep 1
32 citations
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: Dose–effects and time-course
George E. Bigelow, Kenzie L. Preston, John Schmittner, Qunming Dong, David R. Gastfriend> ;Drug and Alcohol Dependence. 2012 Jun 1
7 citations
[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial].
E. M. Krupitskiĭ, Edward V. Nunes, Walter Ling, Ari Illeperuma, David R. Gastfriend, E. A. Blokhina, Bernard L. Silverman> ;Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2012 Jan 1
17 citations
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Helen M. Pettinati, Bernard L. Silverman, John J. Battisti, Robert F. Forman, Edward Schweizer, David R. Gastfriend> ;Alcoholism, Clinical and Experimental Research. 2011 Oct 1
17 citations
Injectable extended-release naltrexone for opioid dependence.
Evgeny Krupitsky, Edward V. Nunes, Walter Ling, Ari Illeperuma, David R. Gastfriend, Bernard L. Silverman> ;Lancet. 2011 Aug 20
70 citations
Cost and utilization outcomes of opioid-dependence treatments.
Onur Baser, Mady Chalk, David A. Fiellin, David R. Gastfriend> ;The American Journal of Managed Care. 2011 Jun 17
26 citations
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Onur Baser, Mady Chalk, Richard A. Rawson, David R. Gastfriend> ;The American Journal of Managed Care. 2011 Jun 17
369 citations
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial
Evgeny Krupitsky, Edward V. Nunes, Walter Ling, Ari Illeperuma, David R. Gastfriend, Bernard L. Silverman> ;Lancet. 2011 Apr 30
59 citations
Intramuscular extended‐release naltrexone: current evidence
David R. Gastfriend> ;Annals of the New York Academy of Sciences. 2011 Jan 1
22 citations
Advancing performance measures for use of medications in substance abuse treatment
Cindy Parks Thomas, Deborah W. Garnick, Constance M. Horgan, Frank McCorry, Amanda Gmyrek, Mady Chalk, David R. Gastfriend, Suzanne Gelber Rinaldo, Joann Albright, Vic...> ;Journal of Substance Abuse Treatment. 2011 Jan 1
28 citations
Long-Term Opioid Blockade and Hedonic Response: Preliminary Data from Two Open-Label Extension Studies with Extended-Release Naltrexone
Charles P. O’Brien, David R. Gastfriend, Robert F. Forman, Edward Schweizer, Helen M. Pettinati> ;The American Journal on Addictions. 2010 Dec 28
18 citations
Comparison of healthcare utilization among patients treated with alcoholism medications.
Tami L. Mark, Leslie B. Montejano, Henry R. Kranzler, Mady Chalk, David R. Gastfriend> ;The American Journal of Managed Care. 2010 Dec 16
6 citations
Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence.
Ron A. Cisler, Bernard L. Silverman, Irina Gromov, David R. Gastfriend> ;Journal of Addiction Medicine. 2010 Sep 1
5 citations
Effects of Naltrexone Treatment for Alcohol-Related Disorders on Healthcare Costs in an Insured Population
Henry R. Kranzler, Leslie B. Montejano, Judith J. Stephenson, Shaohung Wang, David R. Gastfriend> ;Alcoholism, Clinical and Experimental Research. 2010 Jun 1
38 citations
Effect of Extended‐Release Naltrexone (XR‐NTX) on Quality of Life in Alcohol‐Dependent Patients
Helen M. Pettinati, David R. Gastfriend, Qunming Dong, Henry R. Kranzler, Stephanie S. O'Malley> ;Alcoholism, Clinical and Experimental Research. 2009 Feb 1
Join now to see all

Journal Articles

Attitudes and practices on the use of extended-release naltrexone in criminal justice settings
Festinger DS, Dugosh KL, Gastfriend DR, Sierka C, Drug Alc Dependence, 1/1/2017
Open-label study of injectable extended-release naltrexone (XR-NTX) in healthcare professionals with opioid dependence
Earley PH, Zummo J, Memisoglu A, Silverman BL, Gastfriend DR, J Addiction Medicine, 1/1/2017
Specialized community disease management to reduce substance use and hospital readmissions
Chambers JE, Brooks AC, Morrison MF, McKay JR, Gastfriend DR, Drug Alc Dependence, 1/1/2017
A naturalistic evaluation of extended-release naltrexone in clinical practice in Missouri
Crits-Christoph P, Markell HM, Gibbons MBC, Gallop R, Lundy C, Stringer M, Gastfriend DR, J Subst Abuse Treatment, 1/1/2016
Extended-release naltrexone for alcohol and opioid problems in Missouri parolees and probationers
Crits-Christoph P, Lundy C, Stringer M, Gallop R, Gastfriend DR, J Substance Abuse Treatment, 1/1/2015
Matching patients with substance use disorder to optimal level of care with the ASAM Criteria software
Stallvik M, Gastfriend DR, Nordahl HM, J Subst Use, 1/1/2015
Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies
Hartung D, McCarty D, Fu R, Wiest K, Chalk M, Gastfriend DR, Journal of Substance Abuse Treatment, 1/1/2014
Predictive and Convergent Validity of the ASAM Criteria Software in Norway
Stallvik M, Gastfriend DR, Addiction Research & Theory, 1/1/2014
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders
Gastfriend, DR, Ann NY Acad Sci, 1/1/2014
Medication and non-medication treatment of alcohol dependence: A number needed to treat (NNT) analysis
Gastfriend DR, Chalk M, McCarty D, Alcohol Clin Exp Res, 1/1/2013
Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-using adults: Dose–effects and time-course
Bigelow GE, Preston KL, Schmittner J, Dong Q, David R Gastfriend DR, Drug Alc Dependence, 1/1/2012
Advancing performance measures for use of medications in substance abuse treatment
Thomas CP, Garnick DW, Horgan CM, McCorry F, Gmyrek A, Chalk M, Gastfriend DR, Rinaldo SG, Albright J, Capoccia V, Harris AH, Harwood HJ, Greenberg P, Mark T, Un H, Or..., Journal of Substance Abuse Treatment, 1/1/2011
A double-blind, placebo-controlled, multicenter randomized clinical trial of injectable extended-release naltrexone for opioid dependence
Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL, Lancet, 1/1/2011
Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence
Pettinati HM, Silverman BL, Battisti JJ, Forman R, Schweizer E, Gastfriend DR, Alcoholism Clinical and Experimental Research, 1/1/2011
Intramuscular extended-release naltrexone: current evidence
Gastfriend, DR, Ann NY Acad Sci, 1/1/2011
Impact of treatment with intramuscular injectable extended-release naltrexone on counseling and support group participation in patients with alcohol dependence
Cisler RA, Silverman BL, Gromov I, Gastfriend DR, J Addict Med, 1/1/2010
Comparison of healthcare utilization and costs among patients treated with alcohol dependence medications
Mark TL, Montejano L, Kranzler HR, Chalk M, Gastfriend DR, Am J Manag Care, 1/1/2010
Randomized, double-blind, dose-effect evaluation of opioid blockade by extended-release naltrexone
Bigelow GE, Preston KL, Schmittner J, Dong Q, Gastfriend DR, College on Problems of Drug Dependence, 1/21/2007
Design and analysis of trials of combination therapies
Hosking JD, Cisler RA, Couper DJ, Gastfriend DR, Kivlahan DR, Anton RF, J Stud Alcohol, 1/1/2005
Factorial designs in clinical trials: options for combination treatment studies
Couper DJ, Hosking JD, Cisler RA, Gastfriend DR, Kivlahan DR, J Stud Alcohol, 1/1/2005
Physician Substance Abuse—Reply [letter]
Gastfriend DR, JAMA, 1/1/2005
Effects of long-acting injectable naltrexone on durability of drinking outcomes
Gastfriend DR, Dong Q, Loewy J, Silverman B, Ehrich EW, Alcohol Clin Exp Res, 1/1/2005
Effects of lead in abstinence and a goal of abstinence on heavy drinking
O'Malley SS, Garbutt JC, Gastfriend DR, Kranzler HR, Pettinati HM, Illeperuma A, et al., Alcohol Clin Exp Res, 1/1/2005
Patient acceptance of alcoholism pharmacotherapy
Gastfriend DR, Sharon E, Lee S, Alcohol Clin Exp Res, 1/1/2005
Testing Combined Pharmacotherapies and behavioral Interventions in Alcohol Dependence: Rationale and Methods
Combine Study Research Group, Alcoholism: Clinical & Experimental Research, 1/1/2003
Join now to see all

Books/Book Chapters

The ASAM Criteria for Addictive, Substance-Related and Co-occurring Conditions
Mee-Lee D, Shulman GD, Fishman MJ, Gastfriend DR, Miller MMThe Change Companies, Carson City, NVEdition 3rd,2013
Psychotherapy for the Treatment of Substance Abuse
Chapter: Patient Placement Criteria
Gastfriend DR, Mee-Lee DEditors: Galanter M, Kleber HD.American Psychiatric Publishing, Inc., Washington DC2011
Substance Dependence and Co-Occurring Psychiatric Disorders: Best Practices for Diagnosis and Clinical Treatment
Chapter: Choosing treatment services and levels of care: American Society of Addiction Medicine Patient Placement Criteria
Angarita G, Lee S, Gastfriend DREditors: Nunes EV, Selzer J, Levounis P, Davies CA.Civic Research Institute, Inc. Kingston, New Jersey2010
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Alcoholic patients: Acute and chronic
Ross JD, Gastfriend DR, Renner Jr. JAEditors: TA Stern, GL Fricchione, NH Cassem, MS Jellinek, JF Rosenbaum.Saunders, Philadelphia2010
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Drug-addicted patients
Renner Jr. JA, JD Ross, Gastfriend DREditors: TA Stern, GL Fricchione, NH Cassem, MS Jellinek, JF Rosenbaum.Saunders, Philadelphia2010
Massachusetts General Hospital: Guide to Primary Care Psychiatry
Chapter: Chapter 53: The Cocaine or Opiate-Abusing Patient
Gastfriend, D.R. and J.J. O'ConnellEditors: T.A. Stern, J.B. Herman, and P.L. Slavin.McGraw-Hill Medical Publishing Division, New York, NY2004
Drug addicted patients
Chapter: Drug addicted patients
Renner JA, Gastfriend DREditors: T. A. Stern, G. L. Fricchione.Mosby, Boston2004
Addiction Treatment Matching: Research Foundations of the American Society of Addiction Medicine (ASAM) Criteria
Gastfriend, DRThe Haworth Medical Press, Binghamton NY2004
Principles of Addiction Medicine
Chapter: Co-occurring addictive and anxiety disorders
Nitenson N, Gastfriend DREditors: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB. Chevy Chase, MD.American Society of Addiction Medicine, Inc.Edition 3rd,2003
Alcoholism: A Practical Handbook
Chapter: Assessing Medical Consequences of Alcoholism
Kang S, Gastfriend DREditors: Johnson BA, Ruiz P, Galanter M.Lippincott Williams & Wilkins, Baltimore2003
Principles of Addiction Medicine
Chapter: Assessment
Gastfriend DR, Reif S, Baker SL, Najavits LMEditors: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB. Chevy Chase, MD.American Society of Addiction Medicine, Inc.2003
APA Textbook of Substance Abuse Treatment
Chapter: Patient Placement Criteria
Gastfriend, DREditors: Galanter M, Kleber HD.2003
The State of the Art in Addiction Medicine: An Update on the Unifying Concepts of Addiction - Drug Development, Emerging Therapies, and Individual Treatment (Course Syllabus)
Gastfriend DR, Schultz TK, Wilford BBAmerican Society of Addiction Medicine, Inc., Chevy Chase, MD2003
ASAM Patient Placement Criteria for the Treatment of Substance-Related Disorders(ASAM PPC-2R)
Mee-Lee D, Shulman GD, Fishman M, Gastfriend DR, and Griffith JHAmerican Society of Addiction Medicine, Inc., Chevy Chase, MDEdition 2nd,2001
Textbook Of Substance Abuse Treatment
Chapter: Patient Placement Criteria
Gastfriend, DRThe American Psychiatric Press, Washington1999
Principles of Addiction Medicine
Chapter: Section IV: Chapter 3: Assessment Instruments
Gastfriend DR, Baker SL, et al.Editors: N. Miller and M. Doot. Chevy Chase, MD.American Society of Association Medicine, IncEdition 2nd,1998
Abstracts of Clinical Care Guidelines
Chapter: Commentary on Nonpharmacologic approaches to substance abuse treatment
Gastfriend, DRJoint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace IL1998
The Principles and Practice of Addictions in Psychiatry
Chapter: Pharmacological treatments for psychiatric symptoms in addiction populations
Gastfriend, DREditors: N Miller.W.B. Saunders Company, Philadelphia1997
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Alcoholic patients-acute and chronic
Gastfriend DR, Renner JA, Hackett TPEditors: N. H. Cassem, T. A. Stern, J. F. Rosenbaum and M. S. Jellinek.Mosby, Boston1997
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Drug addicted patients
Renner JA, Gastfriend DREditors: N. H. Cassem, T. A. Stern, J. F. Rosenbaum and M. S. Jellinek.Mosby, Boston1997
Challenges in Clinical Practice: Pharmacologic and Psychosocial Strategies
Chapter: When a substance use disorder is the cause of treatment resistance
Gastfriend, DREditors: Pollack MH, Otto MW, Rosenbaum JF.Guilford Publications, Chicago1996
Mental Health Computing
Chapter: Voice interactive computers for attitudinal interviewing
Gitlow S, Gastfriend DREditors: Miller MJ, Hammond KW, Hile MG.Springer, New York1996
Principles of Addiction Medicine
Chapter: Assessment instruments
Gastfriend, DREditors: Miller N.American Society of Addiction Medicine, Washington D.C.1994
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Alcoholism: Acute and Chronic States
Hackett TP, Gastfriend DR, Renner Jr JAEditors: Cassem NH.Mosby-Yearbook Press, ChicagoEdition 3rd,1991
Massachusetts General Hospital Handbook of General Hospital Psychiatry
Chapter: Drug addiction
Renner Jr JA, Gastfriend DREditors: Cassem NH.Mosby-Yearbook Press, ChicagoEdition 3rd,1991
Join now to see all

Abstracts/Posters

Commentary on Nonpharmacologic Approaches to Substance Abuse Treatment
Gastfriend, DR, Abstracts of Clinical Care Guidelines, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, IL, 1/1/1998
Categorical vs. dimensional determination of alcoholic subtype and correlation with severity and personality
Gastfriend DR, Lex BW, Waldman J, Mendelson J, Alcoholism: Clin Exp Research, 1/1/1990

Other

New Horizons for Treatment Strategies
Creed M, Crystal RG, Gastfriend DR, Tyndale RF, The New York Academy of Sciences. The Addicted Brain and New Treatment Frontiers: Sixth Annual Aspen
www.nyas.org/addiction2016-eB
1/1/2016
Treatment matching in substance use disorders (audiotape journal)
Gastfriend, DR, Practical Reviews in Psychiatry
1/1/1996
Diagnosis and treatment matching in alcoholism (audiotape journal)
Gastfriend, DR, Practical Reviews in Psychiatry
1/1/1989
Practical computer applications for psychiatrists. (commissioned by audiotape journal)
Gastfriend, DR, Practical Reviews in Psychiatry
1/1/1985
Join now to see all

Press Mentions

ANNOUNCEMENT: Intent Solutions Announces New Advisory Board Member-- David GastfriendJanuary 17th, 2017
PODCAST: David Gastfriend Discusses the Importance of the ASAM CriteriaDecember 8th, 2014
ASAM Criteria Software Plenary Outlines Impending Product LaunchOctober 13th, 2014
Join now to see all

Grant Support

A Simple Large Trial of Patient‐Centered Care for Opioid Use Disorders in Federally Qualified Healthcare CentersPCORI - The Patient-Centered Outcomes Research Institute2017–2022
Improving Drug Abuse Treatment Planning CriteriaNational Institute On Drug Abuse2000–2004
Core--ClinicalNational Institute On Drug Abuse1997–2002
Validity Of The ASAM Criteria For Drug Abuse TreatmentNational Institute On Drug Abuse1994–2000

Professional Memberships

American Society of Addiction Medicine - ASAM
Member

Industry Relationships

Consultant, IBM Watson - Truven Health AnalyticsProvide health outcomes research and policy guidance and technical assistance to IBM Watson research & evaluation staff and state Medicaid leadership, on behalf of U.S. Centers for Medicare & Medicaid Services (CMS)2016 - Present
Consultant, Rand Corp.Provide scientific expertise for algorithm mapping in clinical decision support and analysis.2016 - Present
Consultant, BioCorRx, Inc.2016 - Present
Consultant, Indivior, Inc.2016 - Present
Scientific Advisory Board Member, Recovery Corporation of America, Inc.2016 - 2017
Consultant, Purdue Pharma2016 - 2016
Consultant, Kaleo, Inc.2016 - 2016
Vice President, Alkermes, Inc.Provided guidance and oversight for the development of monthly injectable naltrexone, addressing basic, clinical RCT, effectiveness, health economic, and criminal justice research for this new formulation, which achieved FDA-approval in the treatment of both alcohol and opioid dependence.Disclosure: Consultant; shareholder2005 - 2013